Stock Pick: Novavax can be a Big Winner in 2017 | Hacked: Hacking Finance

Stock Picks

Stock Pick: Novavax can be a Big Winner in 2017

Posted on .

Stock Pick: Novavax can be a Big Winner in 2017


This article was posted on Saturday, 16:20, UTC.

Novavax (NASDAQ:NVAX) develops vaccines based on protein nanoparticles which can help increase the immune response in patients. It is currently awaiting results of phase 3 trial. A successful result will provide significant bump to the stock and also make it an attractive acquisition target by bigger pharmaceutical companies.

// -- Discuss and ask questions in our community on Workplace. Don't have an account? Send Jonas Borchgrevink an email -- //

RSV F maternal vaccine candidate in phase 3

Data from RSV F vaccine in phase 3 will show its efficacy. We should see the results by the second half of this year. If the results are excellent it will allow Novavax to target 4 million people.

[ecko_annotated header=”Novavax’s RSV F vaccine is the only candidate in phase 3″ annotation=””]

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //


The market opportunity of this vaccine is enormous. Close to 57,000 children younger than 5 years are hospitalized due to RSV infection. Being the only drug can provide significant advantage to Novavax. The RSV F vaccine for maternal immunization is estimated to have annual US cost burden of around $770 million. For older adults this burden is a staggering $28 billion. NVAX will be able to launch the RSV F vaccine for maternal immunization by early 2018 whereas vaccine for older adults can be launched in 2019.

[ecko_annotated header=”Big market opportunity for Novavax vaccines” annotation=””]


Peak sales target

The past success rate of phase 3 drugs getting FDA approval is close to 50%. According to NVAX the market opportunity for maternal immunization vaccine is close to $770 million. This would result in a peak sales estimate of $380 million as there is no other competition for this drug. Valuation of a clinical stage biotech company is between 3-5 times its peak sales. Taking a conservative estimate, this $380 million in peak sales will translate to a $1.14 billion market capitalization for the company. Currently the stock has a market cap of $223 million.

[ecko_annotated header=”Probability of success for a drug at different stages” annotation=””]


Currently the stock is trading at $0.82/share. If the above approval is provided we can see the stock skyrocket to $4-$4.5/share. Becoming an acquisition target soon after approval will also provide a good premium valuation to the stock in a short time.

Risk/Reward associated with the stock

Although the upside for the stock is quite strong at the present moment, it should be noted that everything hinges on RSV F vaccine getting FDA approval. In case this vaccine does not meet the requisite standards we should see a slump in the shares. A similar event happened in September 2016 when RSV F vaccine did not meet the standards for older patients. This led to over 80% fall in its stock price.

[ecko_annotated header=”Fall in NVAX prices after its last drug failure in meeting the standards on older patients in September 2016″ annotation=””]


Investor Takeaway

Novavax is developing RSV F vaccine for Respiratory Syncytial Virus. This vaccine for infants through maternal immunization is in Phase 3 and the results should be declared in the latter half of 2017. If it gets the requisite approval from FDA, it will be the first drug in the market for RSV segment and will have a peak sales market opportunity of $380 million. This can boost the price of the stock to over $4/share from current price of $0.80/share.

If it goes through the acquisition route, the stock valuation can increase much sooner. However, traders much also be aware of the risk associated with this stock. The stock is heavily reliant on the positive outcome of its RSV F vaccine and if this does not happen, we can see a decline in the stock for quite some time.

Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.

Feedback or Requests?

Rohit Chatwal

Rohit Chatwal

  • user

    AUTHOR Ershad

    Posted on 10:27 pm April 22, 2017.

    Hi Rohit,

    Thanks for your article I wanted to ask a questions firstly how does one buy shares into this company? Secondly what are the probality that this new drug gets an approval from the FDA?

    Kind regards

    • user

      AUTHOR Pabloasampras

      Posted on 3:04 am May 1, 2017.

      Hi bud , you can open an independent investing account with Merryl Lynch

  • View Comments (2) ...
    The team:
    Dmitriy Lavrov
    Dmitriy Lavrov is a professional trader, technical analyst and money manager with 10 years of trading experience. He covers Forex, Commodities and Cryptocurrencies. He is among the top 10 most Read More
    Jonas Borchgrevink
    Jonas Borchgrevink is the founder of and He is a serial entrepreneur, trader and investor. He shares his own personal journey on // -- Discuss and ask Read More
    Mate Csar
    Trader and financial analyst, with 10 years of experience in the field. An expert in technical analysis and risk management, but also an avid practitioner of value investment and passive Read More
    Mati Greenspan
    Senior Market Analyst at // -- Discuss and ask questions in our community on Workplace. Don't have an account? Send Jonas Borchgrevink an email -- // Important: Never invest Read More
    Rakesh Upadhyay
    Rakesh Upadhyay is a Technical Analyst and Portfolio Consultant for The Summit Group. He has more than a decade of experience as a private trader. His philosophy is to use Read More
    Pamela Meropiali
    Account Manager
    Pamela Meropiali is responsible for users on // -- Discuss and ask questions in our community on Workplace. Don't have an account? Send Jonas Borchgrevink an email -- // Read More
    Joseph Young
    Joseph Young is a finance and tech journalist & analyst based in Hong Kong. He has worked with leading media and news agencies in the technology and finance industries, offering Read More
    Weekly Recap Asset Current Value Weekly Change S&P 500 2345…